Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 13.01 · gapped above the open, then crossed back over prior close. High/low 13.06 at 4:00 am ET, 12.51 at 11:15 am ET.
Replimune Group, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“We have entered into agreements with BMS for the supply of nivolumab, its anti-PD-1 therapy, for use in connection with our ongoing IGNYTE Phase 1/2 trials with RP1, our Phase 1/2 clinical trial with RP2 and our Phase 1 and Phase 2 clinical trials with RP3 where we decide to use nivolumab.”
FILING10-K0001628280-26-045886cik 0001737953
“We have also entered into a clinical collaboration agreement with Regeneron, which includes the supply of cemiplimab, its anti-PD-1 therapy, for clinical trials conducted thereunder.”
FILING10-K0001628280-26-045886cik 0001737953
“Additionally, our signal finding study in HCC is being developed in combination with atezolizumab and bevacizumb under a supply and clinical collaboration agreement with Roche.”
FILING10-K0001628280-26-045886cik 0001737953
“We participate, through our subsidiary in the United Kingdom, in the research and development program provided by the United Kingdom tax relief program, such that a percentage of up to 16.2% of our qualifying research and development expenditures are reimbursed by the United Kingdom government, and such incentives are reflected as other income.”
FILING10-K0001628280-26-045886cik 0001737953
“In connection with the Settlement Agreement, we entered into a License and Covenant Agreement with Amgen in which we agreed to pay Amgen low single-digit royalty payments on net sales of our products that, but for the license, could be found to infringe a valid Amgen patent on a country-by-country and product-by-product basis.”
FILING10-K0001628280-26-045886cik 0001737953
“On October 6, 2022 we and certain of our subsidiaries entered into a Loan and Security Agreement, or the Hercules Loan Agreement with Hercules Capital, Inc., or Hercules, in its capacity as administrative agent and collateral agent and as a lender, which such agreement was subsequently amended in June 2023, December 2023 and January 2026.”
FILING10-K0001628280-26-045886cik 0001737953
“In March 2023, the FDIC took control of Silicon Valley Bank, or SVB, where we previously held a portion of our cash.”
FILING10-K0001628280-26-045886cik 0001737953
Watchlist prices, news filtered to it, and its next report on your desk.
Replimune Group, Inc. has 7 disclosed suppliers and 0 disclosed customers. Each one is named in an SEC filing, either Replimune Group, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
No filing we have read names a customer of Replimune Group, Inc.. Customers appear here when Replimune Group, Inc. names them, or when a company names Replimune Group, Inc. as a supplier in its own annual report.
REPL (Replimune Group, Inc.) has 7 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: REGN −2.23%, in healthcare.